PTHS (Pelthos Therapeutics) Moat Score: 2/10 (As of Jun. 29, 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Moat Score?

Pelthos Therapeutics PTHS -0.62% 8 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 1,402 Biotechnology companies, Pelthos Therapeutics ranks better than 58.06% on this metric.

Pelthos Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Pelthos Therapeutics has No Moat: Pelthos Therapeutics Inc has very weak competitive advantages. It lacks market leadership, significant customer switching costs, and strong brand strength, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pelthos Therapeutics might have No Moat - Very weak/transient advantages.

Pelthos Therapeutics  (AMEX:PTHS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pelthos Therapeutics Moat Score Related Terms

PTHS vs CGTX, BDTX, CBUS: Moat Score Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pelthos Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's Moat Score falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Pelthos Therapeutics (PTHS) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pelthos Therapeutics ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Pelthos Therapeutics' Moat Score too high?
Pelthos Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Pelthos Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Pelthos Therapeutics ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Moat Score compare to CGTX and BDTX?
According to the Biotechnology industry distribution chart, Pelthos Therapeutics ranks #588 out of 1402 companies for Moat Score. This puts Pelthos Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Pelthos Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pelthos Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pelthos Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price